1.71  0.09 (5.56%)		11-21 16:00
Open: 1.64 High: 1.71 Volume: 141,148		Pre. Close: 1.62 Low: 1.61 Market Cap: 60(M)

Short term
Mid term
Targets	6-month :	2.15	1-year :	2.32
Resists	First :	1.84	Second :	1.99
Pivot price	1.79
Supports	First :	1.6	Second :	1.33
MAs	MA(5) :	1.68	MA(20) :	1.81
	MA(100) :	1.94	MA(250) :	2.1
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	15.8	D(3) :	18.3
RSI	RSI(14): 41.7
52-week	High :	7	Low :	1.12

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ OSTX ] has closed above bottom band by 27.2%. Bollinger Bands are 6.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.71 - 1.72	1.72 - 1.73
Low:	1.59 - 1.6	1.6 - 1.61
Close:	1.69 - 1.71	1.71 - 1.73

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Fri, 21 Nov 2025
D. Boral Capital Maintains OS Therapies (OSTX) Buy Recommendation - Nasdaq

Fri, 21 Nov 2025
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25 - MarketScreener

Fri, 21 Nov 2025
OS Therapies (NYSE American: OSTX) posts 75% OS vs 40% in Phase 2b osteosarcoma study - Stock Titan

Fri, 21 Nov 2025
FY2025 EPS Forecast for OS Therapies Decreased by Analyst - MarketBeat

Thu, 20 Nov 2025
OS Therapies (NYSE American: OSTX) plans OS Animal Health spinoff, targets H1 2026 listing - Stock Titan

Wed, 19 Nov 2025
OS Therapies (NYSEAMERICAN:OSTX) Price Target Lowered to $17.00 at Lake Street Capital - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Biotechnology
Shares Out	21 (M)
Shares Float	17 (M)
Held by Insiders	24.8 (%)
Held by Institutions	0 (%)
Shares Short	9 (K)
Shares Short P.Month	0 (K)

EPS	-0.32
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-4.52
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.16
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-5.35
PEG Ratio	0
Price to Book value	-0.38
Price to Sales	0
Price to Cash Flow	-10.92

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.